Review
British Journal of Cancer (2009) 100, 13–18. doi:10.1038/sj.bjc.6604822 www.bjcancer.com
Published online 16 December 2008
Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer
W M van Weerden1, C Bangma1 and R de Wit2
- 1Department of Urology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
- 2Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
Correspondence: Dr WM van Weerden, Department of Urology, Josephine Nefkens Institute, room BE362, Erasmus MC Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: w.vanweerden@erasmusmc.nl
Received 26 June 2008; Revised 21 October 2008; Accepted 18 November 2008; Published online 16 December 2008.
Abstract
With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.
Keywords:
hormone refractory prostate cancer, xenografts, novel therapeutics, PSA biomarker
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
